CognitiveResearch
PE-22-28
Also known as: PE22-28 · Spadin analog
A spadin analog studied for rapid antidepressant-like effects, working through TREK-1 potassium channel modulation.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~2–4 hours
Typical Dose
100–500 mcg
Administration
Subcutaneous injection or intranasal
Mechanism of Action
Blocks TREK-1 potassium channels to enhance serotonergic and noradrenergic neurotransmission, producing fast-acting mood elevation.
Key Research Areas
antidepressantcognitiveTREK-1mood
Frequently Asked Questions
What is PE-22-28?▾
A spadin analog studied for rapid antidepressant-like effects, working through TREK-1 potassium channel modulation.
How does PE-22-28 work?▾
Blocks TREK-1 potassium channels to enhance serotonergic and noradrenergic neurotransmission, producing fast-acting mood elevation.
What is the recommended dosage for PE-22-28?▾
The typical research dosage is 100–500 mcg, administered via Subcutaneous injection or intranasal. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of PE-22-28?▾
The half-life of PE-22-28 is approximately ~2–4 hours. This affects dosing frequency and timing in research protocols.
Is PE-22-28 FDA approved?▾
PE-22-28 is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about PE-22-28 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.